UNSPSC 51283915: Sulfalene or sulfamethopyrazine

This classification denotes a sulfonamide anti-infective agent with the molecular formula C11H12N4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T6BL4ZC15G, chemically known as sulfanilamide, n(sup 1)-(3-methoxypyrazinyl)- but generally known as sulfalene, which bears US NIH Compound Identifier 9047. European Medicines Agency schedules Sulfalene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10705MIG. The term SULFALENE is an International Non-Proprietary Name.

UNSPSC 51283915 Sulfalene or sulfamethopyrazine is a Commodity code for a specific pharmaceutical active ingredient, but recent state and local procurement activity tagged to this code does not reflect purchases of sulfalene or sulfamethopyrazine itself. Instead, the code appears in records for broader pharmaceutical supply and emergency-response medical products—including antibiotic tablets (doxycycline and ciprofloxacin) and naloxone with drug deactivation systems—suggesting either misclassification in state and local procurement systems or use of the code as a catch-all for pharmaceutical and medical-supply buys that do not map cleanly to narrower commodity definitions. The issuing bodies soliciting under this code include state health departments and county governments pursuing community health and emergency-response initiatives through competitive bidding processes, typically via cooperative purchasing vehicles such as MMCAP Infuse or direct IFB mechanisms.

Recent activity spans Illinois and Florida. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026, for doxycycline and ciprofloxacin tablets under an IFB process (Solicitation 26482DPHPREPDB53392), reflecting a completed award rather than an open opportunity. Seminole County, Florida posted an IFB on June 30, 2026 (IFB60459723LAS), seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023—though this posting date and due date fall outside current procurement windows, indicating either archived or misdated records in the source. Both opportunities required electronic bid submission, compliance with drug-free workplace and E-Verify requirements, and fixed-fee pricing structures. No explicit set-asides for disadvantaged enterprises were identified in either record.